Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GW Pharmaceuticals PLC

www.gwpharm.com

Latest From GW Pharmaceuticals PLC

Keeping Track: NME Approvals For Evenity And Balversa; Non-NME Approvals For Dovato And Keytruda; But An RTF For Fintepla

The latest drug development news and highlights from our US FDA Performance Tracker. 
US FDA Performance Tracker Drug Review

US FDA Filing Mistake For Fintepla Dents Zogenix

Zogenix seems only to have itself to blame for an unexpected refusal to file letter from the US agency for its novel treatment for Dravet syndrome that sent its shares tumbling by 31% on NASDAQ in after-hours trading.

Drug Review Policy & Regulation

CBD Policies From CHPA, CRN Follow FDA; AHPA Acts Ahead Of Agency

CHPA says FDA's enforcement discretion for hemp and CBD supplements isn't sufficient oversight as potentially unsafe products are available. CRN announces three CBD firms as members, but says "many companies marketing products as containing CBD are not" compliant. Guidance policy adopted in March says AHPA doesn't agree or disagree with FDA but some CBD firms and legal experts assert the agency is "inaccurate, and have presented certain arguments that potentially counter FDA’s position."

Wellness Health

Biohaven Pays $105m For Turbo Boost In Migraine Drug Review Race

Biohaven has acquired a priority review voucher from GW Pharma to accelerate the US review of rimegepant, its oral CGRP receptor antagonist for migraine. The firm is competing with Allergan and Lilly in a race to get the next oral treatment approved.

Drug Review Neurology
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Inflammation
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • GW Pharmaceuticals PLC
  • Senior Management
  • Justin Gover, CEO
    Scott Giacobello, CFO
    Chris Tovey, COO
    Volker Knappertz , MD, CMO
  • Contact Info
  • GW Pharmaceuticals PLC
    Phone: (44) 1223 266800
    Sovereign House
    Vision Park
    Histon, Cambridge, CB24 9BZ
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register